Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...
Hosted on MSN
Sutro Biopharma’s promising phase 1 study on STRO-004: A potential game-changer in cancer treatment
Sutro Biopharma (STRO) announced an update on their ongoing clinical study. Study Overview: Sutro Biopharma is conducting a Phase 1 open-label study titled A Phase 1 Open-Label Study to Evaluate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback